FIRCA Breast Cancer Case-Control Study in Slovakia

斯洛伐克 FIRCA 乳腺癌病例对照研究

基本信息

  • 批准号:
    6839972
  • 负责人:
  • 金额:
    $ 3.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-02-01 至 2008-01-31
  • 项目状态:
    已结题

项目摘要

EXCEED THE SPACE PROVIDED. This research will be done primarily in Slovakia as a FIRCA supplement to NIH grant # P01 CA82267 (Project 4). Breast cancer is the most commonly diagnosed cancer in women in SIovakia, and the leading cause of death. There are emerging data that fetal, early childhood and adolescent exposures related to growth, body mass and physical activity may be associated with the risk of breast cancer. We propose to evaluate these questions in a hospital-based case-control study in western Slovakia. Cases (N=250)will be women aged 20-70 years who are first diagnosed with invasive breast cancer from 1/1/2003 through 6/30/2005 and are residents of Trnava or Senica districts at the time of diagnosis. Cases will be rapidly ascertained through surveillance of the district hospitals in Trnava and Senica. Controls (N=250) will be women with no history of breast cancer, aged 20-70 years, and who are residents of Trnava or Senica district. Controls will be frequency matched to cases by age group and district, and will be randomly selected from the primary care medical practices in each district. Participants will complete a standardized in-person interview and provide a blood sample. Through interviews and abstraction of medical/population records, we will collect data on fetal exposures (birthweight, birth length, gestational age, twinning/zygosity, pre-eclampsia, etc.), childhood anthropometrics (height and weight at various ages), and adolescent exposures (anthropometrics, age at menarche). We will also collect data on other key breast cancer risk factors, including reproductive and adult anthropometric variables, in order to evaluate confounding. Genomic DNA will also be collected from peripheral blood, and banked in order to conduct future studies on the role of common genetic polymorphisms in candidate genes, as well as gene-environment interactions, in the etiology of breast cancer. There is sufficient statistical power to test the a priori hypotheses of interest. We have assembled an international research team for this study. This study will address an important scientific question in breast cancer etiology, and these data would be expected to better inform the primary prevention of the disease. This study will also develop infrastructure and experience in Slovakia for the conduct of cancer epidemiology studies, and generate the necessary preliminary data for expansion of this research effort. PERFORMANCE SITE ========================================Section End===========================================
超出提供的空间。这项研究将主要在斯洛伐克进行,作为美国国立卫生研究院#P01 CA82267(项目4)补助金的FIRCA补充。乳腺癌是锡奥瓦基亚妇女最常被诊断出的癌症,也是主要的死亡原因。新出现的数据显示,胎儿、幼儿和青少年暴露在与生长、体重和体力活动相关的环境中,可能与患乳腺癌的风险有关。我们建议在斯洛伐克西部一项以医院为基础的病例对照研究中评估这些问题。病例(N=250)将是20-70岁的妇女,她们在2003年1月1日至2005年6月30日期间首次被诊断为浸润性乳腺癌,确诊时是特纳瓦州或塞尼卡区的居民。将通过监测特纳瓦和塞尼察的地区医院迅速查明病例。对照(N=250)将是没有乳腺癌病史、年龄在20-70岁、居住在特纳瓦或塞尼卡区的妇女。对照将按年龄组和地区与病例频率匹配,并将从每个地区的初级保健医疗实践中随机选择。参与者将完成标准化的面谈并提供血样。通过采访和摘录医疗/人口记录,我们将收集有关胎儿接触的数据(出生体重、出生长度、孕龄、双胞胎/合子、先兆子痫等)、儿童人体测量学(不同年龄的身高和体重)和青少年接触的数据(人体测量学、初潮年龄)。我们还将收集其他关键乳腺癌风险因素的数据,包括生殖和成人人体测量变量,以评估混杂情况。还将从外周血中收集基因组DNA,并将其储存起来,以进行未来对候选基因中常见基因多态的作用以及基因与环境的相互作用在乳腺癌病因中的研究。有足够的统计能力来检验感兴趣的先验假设。我们为这项研究组建了一个国际研究团队。这项研究将解决乳腺癌病因学中的一个重要科学问题,这些数据有望更好地为乳腺癌的初级预防提供信息。这项研究还将在斯洛伐克发展进行癌症流行病学研究的基础设施和经验,并为扩大这项研究努力提供必要的初步数据。表演网站========================================Section End===========================================

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES R CERHAN其他文献

JAMES R CERHAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES R CERHAN', 18)}}的其他基金

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)
淋巴瘤流行病学结果 (LEO) 队列研究(补充)
  • 批准号:
    10626269
  • 财政年份:
    2022
  • 资助金额:
    $ 3.46万
  • 项目类别:
Genetic Predictors of Early Clinical Failure in Diffuse Large B Cell Lymphoma
弥漫性大 B 细胞淋巴瘤早期临床失败的遗传预测因素
  • 批准号:
    10219978
  • 财政年份:
    2017
  • 资助金额:
    $ 3.46万
  • 项目类别:
Genetic Predictors of Early Clinical Failure in Diffuse Large B Cell Lymphoma
弥漫性大 B 细胞淋巴瘤早期临床失败的遗传预测因素
  • 批准号:
    9751227
  • 财政年份:
    2017
  • 资助金额:
    $ 3.46万
  • 项目类别:
Genetic Predictors of Early Clinical Failure in Diffuse Large B Cell Lymphoma
弥漫性大 B 细胞淋巴瘤早期临床失败的遗传预测因素
  • 批准号:
    9380363
  • 财政年份:
    2017
  • 资助金额:
    $ 3.46万
  • 项目类别:
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
淋巴瘤流行病学结果 (LEO) 队列研究
  • 批准号:
    10381614
  • 财政年份:
    2015
  • 资助金额:
    $ 3.46万
  • 项目类别:
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
淋巴瘤流行病学结果 (LEO) 队列研究
  • 批准号:
    9334403
  • 财政年份:
    2015
  • 资助金额:
    $ 3.46万
  • 项目类别:
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
淋巴瘤流行病学结果 (LEO) 队列研究
  • 批准号:
    9096776
  • 财政年份:
    2015
  • 资助金额:
    $ 3.46万
  • 项目类别:
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
淋巴瘤流行病学结果 (LEO) 队列研究
  • 批准号:
    9379101
  • 财政年份:
    2015
  • 资助金额:
    $ 3.46万
  • 项目类别:
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
淋巴瘤流行病学结果 (LEO) 队列研究
  • 批准号:
    10593053
  • 财政年份:
    2015
  • 资助金额:
    $ 3.46万
  • 项目类别:
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
淋巴瘤流行病学结果 (LEO) 队列研究
  • 批准号:
    8888571
  • 财政年份:
    2015
  • 资助金额:
    $ 3.46万
  • 项目类别:

相似海外基金

Intelligent Breast Cancer DiagnOsis and MonItoring Therapeutic Response Training Network (CanDoIt)
智能乳腺癌诊断和监测治疗反应训练网络(CanDoIt)
  • 批准号:
    EP/Y03693X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.46万
  • 项目类别:
    Research Grant
From single-cell transcriptomic to single-cell fluxomic: characterising metabolic dysregulations for breast cancer subtype classification
从单细胞转录组到单细胞通量组:表征乳腺癌亚型分类的代谢失调
  • 批准号:
    EP/Y001613/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.46万
  • 项目类别:
    Research Grant
Preclinical validation of synthetic biomolecules to treat Breast Cancer from AI-enabled discovery of novel lncRNA therapeutic targets.
通过人工智能发现新型 lncRNA 治疗靶点,对合成生物分子治疗乳腺癌进行临床前验证。
  • 批准号:
    10110204
  • 财政年份:
    2024
  • 资助金额:
    $ 3.46万
  • 项目类别:
    Launchpad
Quad negative breast cancerに対する新たなプレシジョン・メディシン治療戦略
四阴性乳腺癌精准医学治疗新策略
  • 批准号:
    24K11748
  • 财政年份:
    2024
  • 资助金额:
    $ 3.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ESR1 mutation profiling identifies potential drivers of metastatic breast cancer
ESR1 突变分析确定了转移性乳腺癌的潜在驱动因素
  • 批准号:
    MR/X018199/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.46万
  • 项目类别:
    Research Grant
Spatial-BrTME: Multicellular spatial dynamics of immunotherapy response in breast cancer
Spatial-BrTME:乳腺癌免疫治疗反应的多细胞空间动力学
  • 批准号:
    EP/Y014995/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.46万
  • 项目类别:
    Research Grant
Development of comprehensive PET imaging for precise diagnosis of breast cancer
开发用于乳腺癌精确诊断的综合PET成像
  • 批准号:
    23H02856
  • 财政年份:
    2023
  • 资助金额:
    $ 3.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of internal radiation therapy agents for refractory breast cancer based on phase-shift using focused ultrasound
基于聚焦超声相移的难治性乳腺癌体内放射治疗剂的开发
  • 批准号:
    23H02866
  • 财政年份:
    2023
  • 资助金额:
    $ 3.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The early detection of breast cancer using field cacerization.
使用现场癌症化早期检测乳腺癌。
  • 批准号:
    23K08094
  • 财政年份:
    2023
  • 资助金额:
    $ 3.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of CD44 bearing TJA-II binding glycans in therapy-resistant subset of triple negative breast cancer
携带 CD44 的 TJA-II 结合聚糖在三阴性乳腺癌耐药亚型中的作用
  • 批准号:
    23K06748
  • 财政年份:
    2023
  • 资助金额:
    $ 3.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了